Request Demo
AstraZeneca studies highlight burden of COVID-19 for immunocompromised
18 Oct 2023
VaccineClinical ResultImmunotherapymRNA
Two AstraZeneca studies have highlighted the continued significant and disproportionate burdens of COVID-19 on immunocompromised (IC) individuals.
CoveAstraZeneca 30 million individuals, the INFORM and EPOCH real-world studies showed that IC indiCOVID-19have a higher rate of severe outcomes from COVID-19 compared to the general population.
Including around 12 million participants aged 12 years and older in England, the INFORM study aimed to assess clinical outcomes and utilisation of heaCOVID-19resources in relation to COVID-19.
The EPOCH study conducted an extensive insurance claims database of around 17 million people, providing real-world data on COVID-19 risks and outcomes in IC and non-IC populations witCOVID-19US.
The data revealed that 22% of all COVID-19 hospitalisations consisted of IC individuals, along with 28% of ICU admissions aCOVID-19f deaths in England.
People who are IC have a weakened COVID-19ystem and are more susceptible to illness with COVID-19 or could be sick for a longer period of time.
Additionally, as with other vaccines, COVID-19 vaccines are not as effective in IC indiviCOVID-19e to an inability to produce a robust protective response to the vaccine.
The results from the studies revealed COVID-19 vaccinesCOVID-19spite receiving repeated doses of COVID-19 vaccines, IC individuals’ risk of COVID-19 hospitalisations was 14 times greater than that of the general population.
Data from EPOCH showed that the mean total costs for hospitalisations associatedCOVID-19 vaccinesCOVID-19e first COVID-19 diagnosis for IC pCOVID-19was estimated at nearly $1bn, with a mean cost of $64,029 per patient and mean length of hospitalisation stay of 15 days.
Paul Moss, professor of haematology at the University of Birmingham and INFORM investigator, saiCOVID-19RM and EPOCH are the first large-scale studies that jointly provide detailed insight into the impact that COVID-19 continues to have on those patient groups across different geographies.”
Hugh Montgomery, professor of intensive carUniversity of Birmingham CollINFORMndon, said: “AcceleratINFORMhe] development of new therapies that could help protect these vulnerable individuals from COVID-19 and COVID-19hey can properly manage their underlying conditions remains an urgent health priority.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.